Neonatal Pharmacology

Neonatal Pharmacology - Tiny Patients, Unique Rules

Neonates aren't small adults; unique physiology alters drug handling.

• Key Physiological Differences:
  • Body Composition: ↑ Total Body Water (TBW, 70-75%), ↓ Body Fat. Impacts drug Volume of Distribution ($V_d$).
  • Organ Immaturity:
    • Liver: ↓ metabolic enzymes (e.g., glucuronidation).
    • Kidneys: ↓ Glomerular Filtration Rate (GFR).
    • Result: ↓ drug clearance, ↑ drug half-life ($t_{1/2}$).
  • Protein Binding: ↓ albumin → ↑ free drug. Risk: bilirubin displacement (e.g., sulfonamides ⚠️).
  • Blood-Brain Barrier (BBB): ↑ permeability → ↑ CNS drug effects.
• Consequences:
  • Altered Pharmacokinetics (ADME) & Pharmacodynamics (PD).
  • ↑ drug sensitivity & Adverse Drug Reaction (ADR) risk.
• Dosing:
  • Weight-based (mg/kg); Therapeutic Drug Monitoring (TDM) often vital.

⭐ Gray baby syndrome with chloramphenicol highlights neonatal toxicity risk due to immature glucuronidation pathways (Phase II metabolism).

Neonatal Pharmacology - ADME Adventures

• Absorption (A):
  • Oral: Gastric pH ↑, emptying ↓ & erratic.
  • IM: ↓, erratic (↓ muscle mass/flow).
  • Percutaneous: ↑ (thin skin, ↑ BSA:weight).
• Distribution (D):
  • TBW ↑ (~75-85%), ECF ↑. Body fat ↓.
  • Protein binding ↓ (↓ albumin, ↑ free drug, bilirubin displacement).
  • BBB: ↑ permeability.
• Metabolism (M):
  • Hepatic enzymes immature: Phase I & II (glucuronidation) ↓.
  • CYP450 activity ↓.
• Excretion (E):
  • Renal function immature: GFR ↓ (term ~30-40% adult), tubular function ↓.
  • Drug half-life prolonged.

⭐ Deficient glucuronidation in neonates (e.g., with chloramphenicol) can lead to severe toxicity like Grey Baby Syndrome.

Neonatal Pharmacology - Precision Pays Off

• Unique Physiology: Immature organ systems significantly alter drug handling.

• ADME Peculiarities:

  • Absorption: Variable; ↑ transdermal. Gastric pH ↑, emptying ↓.
  • Distribution: ↑ Total Body Water (TBW), ↓ body fat, ↓ protein binding (results in ↑ free drug concentration).
  • Metabolism: Hepatic enzyme activity ↓ (especially glucuronidation Phase II reactions).
  • Excretion: Glomerular Filtration Rate (GFR) ↓, tubular secretion/reabsorption ↓.

• Dosing Strategy: Crucially weight-based (mg/kg); adjust for gestational & postnatal age. Therapeutic Drug Monitoring (TDM) essential for narrow therapeutic index drugs (e.g., aminoglycosides, vancomycin).

• High-Risk Drugs & Concerns:

  • Chloramphenicol: Gray baby syndrome.
  • Sulfonamides: Kernicterus (bilirubin displacement).
  • Aminoglycosides (e.g., Gentamicin): Nephrotoxicity, Ototoxicity.
  • Caffeine Citrate: Standard for apnea of prematurity.

⭐ Chloramphenicol causes Gray Baby Syndrome due to neonates' impaired glucuronidation capacity (deficient UDP-glucuronyl transferase), leading to drug accumulation and cardiovascular collapse.

Neonatal Pharmacology - Cautionary Tales

• Chloramphenicol: Grey baby syndrome (due to ↓ UDP-glucuronyl transferase activity).
• Sulfonamides: Kernicterus (bilirubin displacement from albumin). Avoid in neonates & late pregnancy.
• Tetracyclines: Permanent teeth discoloration, ↓ bone growth. Contraindicated.
• Benzyl Alcohol (preservative): Gasping syndrome (metabolic acidosis, respiratory failure; potentially fatal).
• Aminoglycosides (e.g., Gentamicin, Amikacin): Ototoxicity, nephrotoxicity. Dose carefully; Therapeutic Drug Monitoring (TDM) crucial.
• Opioids (maternal or neonatal): Respiratory depression, Neonatal Abstinence Syndrome (NAS).
• Hexachlorophene (topical antiseptic): Neurotoxicity (vacuolar encephalopathy) if absorbed systemically.
• Aspirin: Potential Reye's syndrome link; generally avoid.
• Indomethacin: Used for PDA closure; risks include Necrotizing Enterocolitis (NEC), GI perforation, renal dysfunction.

⭐ Chloramphenicol causes Grey Baby Syndrome in neonates due to deficient UDP-glucuronyl transferase activity, leading to drug accumulation, cyanosis, and cardiovascular collapse.

High‑Yield Points - ⚡ Biggest Takeaways

• Neonatal physiology significantly alters drug pharmacokinetics (Absorption, Distribution, Metabolism, Excretion).
• Gastric emptying is delayed and intestinal motility irregular, affecting oral drug absorption.
• Total body water is increased, and body fat is decreased, impacting drug volume of distribution.
• Hepatic metabolism (e.g., glucuronidation) is immature, leading to increased drug half-life.
• Renal excretion (glomerular filtration rate) is decreased, prolonging drug elimination.
• Plasma protein binding is reduced, leading to higher free drug concentrations.
• Key drugs needing caution: chloramphenicol (Gray baby syndrome), sulfonamides (kernicterus), opioids (respiratory depression).